DaVita HealthCare Partners’s Neutral Rating Reaffirmed at Zacks (DVA)
DaVita HealthCare Partners (NYSE:DVA)‘s stock had its “neutral” rating restated by Zacks in a research report issued on Thursday, Analyst Ratings.Net reports. They currently have a $60.00 price target on the stock. Zacks‘ price objective would indicate a potential upside of 4.60% from the company’s current price.
Zacks‘ analyst wrote, “We reiterate our Neutral recommendation on DaVita HealthCare following the second quarter earnings that lagged the Zacks Consensus Estimate but surpassed the prior-year quarter’s earnings. Strong revenues and a higher number of treatments were partially offset by higher expenses. The balance sheet also improved with lower debt and higher shareholder equity. Moreover, higher cash flow, rapidly expanding international presence and an active domestic acquisition strategy are the other positive factors. However, high dependence on commercial payors and government reimbursements raise concerns. Overall, an improved outlook for the remainder of 2013 and the merger with HealthCare Partners provide optimism for the near and long term. “
DaVita HealthCare Partners (NYSE:DVA) traded up 0.98% on Thursday, hitting $57.92. 590,755 shares of the company’s stock traded hands. DaVita HealthCare Partners has a one year low of $52.23 and a one year high of $65.665. The stock has a 50-day moving average of $56.47 and a 200-day moving average of $59.. The company has a market cap of $12.314 billion and a price-to-earnings ratio of 20.33.
DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.84 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.84. The company had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.88 billion. During the same quarter in the previous year, the company posted $1.49 earnings per share. The company’s revenue for the quarter was up 50.1% on a year-over-year basis. Analysts expect that DaVita HealthCare Partners will post $3.78 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on DVA. Analysts at Atlantic Securities initiated coverage on shares of DaVita HealthCare Partners in a research note to investors on Thursday. They set an “overweight” rating on the stock. Separately, analysts at Piper Jaffray Cos. cut their price target on shares of DaVita HealthCare Partners from $135.00 to $132.00 in a research note to investors on Wednesday, August 7th. Finally, analysts at RBC Capital downgraded shares of DaVita HealthCare Partners from an “outperform” rating to a “sector perform” rating in a research note to investors on Wednesday, August 7th. They now have a GBX 115 ($1.85) price target on the stock, down previously from GBX 127 ($2.04). One analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $120.83.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.